跳至主要内容
临床试验/JPRN-UMIN000005873
JPRN-UMIN000005873已完成1 期

Phase I Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for EGFR Mutations Non-Small Cell Lung Cancer - Phase I Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for EGFR Mutations Non-Small Cell Lung Cancer

Hamamatsu University School of Medicine, First Department of Surgery0 个研究点目标入组 1 人开始时间: 2011年6月29日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
1

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Diagnosed mutation or heterozygosity of UGT1A1*6/*28. 2)Serious drug allergy. 3)Interstitial pneumonia documented obviously in chest X ray. 4)massive pleural or pericardial effusion ,or ascites. 5)active severe infections. 6)Active synchronous malignancies. 7)Pregnant or beeast-feeding woman or patient who doesn't agree to contraception. 8)Serious psychological disease. 9)brain metastasis. 10)Clinically significant heart disease (myocardial infarction within 12 months, etc.). 11)Uncontrolled diabetes mellitus. 12)Watery diarrhea. 13)Ileus or bowel obstruction. 14)bleeding that requires medication or transfusion. 15)Clinically significant complication. 16)Investigator's judgement.

研究者

发起方
Hamamatsu University School of Medicine, First Department of Surgery

相似试验